Oxford Nanopore reported a 22% increase in 2025 revenue while disclosing a strategic restructuring that included job reductions and a narrower product focus. The company said it cut costs, ended active sales of its ElysIon platform and will discontinue the PromethIon 2 Solo to concentrate on high‑priority opportunities and customer automation compatibility. The regulatory filing detailed £22.6 million in restructuring costs and headcount shifts across R&D, production and commercial teams. Oxford Nanopore stated the changes aim to simplify the portfolio and accelerate investment in core technologies as demand for nanopore sequencing grows in research and clinical markets.